TG Therapeutics, Inc. (NKB2)
XDUS 
Summary
NKB2 Chart
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-year Q1 sales growth and strong market momentum. Phase 3 ENHANCE trial success with single 600 mg IV BRIUMVI dosing supports label expansion and competitive positioning in the RMS market.
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
TG Therapeutics, Inc. (NKB2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TG Therapeutics, Inc. ever had a stock split?
TG Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael S. Weiss CEO | XDUS Exchange | US88322Q1085 ISIN |
| US Country | 352 Employees | - Last Dividend | 30 Apr 2012 Last Split | 14 Dec 1995 IPO Date |
Overview
TG Therapeutics, Inc. is a commercially operational biopharmaceutical entity dedicated to the identification, development, and dissemination of innovative treatments aimed at B-cell mediated diseases across both the United States and the global stage. Founded in 1993 and headquartered in Morrisville, North Carolina, TG Therapeutics has established itself as a pioneer in the field of autoimmune and hematological disorders. Through a combination of in-house R&D and strategic licensing or collaboration agreements with entities such as LFB Biotechnologies S.A.S, GTC Biotherapeutics, Ildong Pharmaceutical Co. Ltd., Rhizen Pharmaceuticals, Jiangsu Hengrui Medicine Co., Novimmune SA, and Checkpoint Therapeutics, Inc., the company has succeeded in creating a diverse portfolio of products and investigational medicines poised for commercial deployment and clinical exploration.
Products and Services
- BRIUMVI (anti-CD20 monoclonal antibody)
Approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. As an anti-CD20 monoclonal antibody, BRIUMVI represents a targeted therapeutic approach intended to alter the course of RMS by modulating the immune system's attack on the nervous system.
- Umbralisib (oral PI3K-delta inhibitor)
This oral therapy is focused on the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). By inhibiting the PI3K-delta pathway, a critical component of B-cell receptor signaling in many blood cancers, umbralisib aims to halt the progression of these malignancies.
- TG-1701 (orally available BTK inhibitor)
TG-1701 is an innovative, orally administered Bruton's tyrosine kinase (BTK) inhibitor that showcases selectivity and potency against BTK in preclinical studies. Its development is aimed at treating a variety of B-cell malignancies by blocking a key signal that promotes cancer cell survival and proliferation.
- TG-1801 (bispecific CD47 and CD19 antibody)
This investigational bispecific antibody targets CD47 and CD19, two proteins involved in the immune evasion of cancer cells. By engaging both targets, TG-1801 is designed to promote the phagocytosis of cancer cells by the immune system, offering a novel approach for the treatment of hematological cancers.
